Small biomarker analysis finds no significant changes after 10 HBOT sessions

A Pilot Investigation of Endocannabinoid System Markers and Lipopolysaccharide Responses to 10 Sessions of Hyperbaric Oxygen Therapy.

Medical science monitor : international medical journal of experimental and clinical research • • Clinical Trial • Highly Relevant
🤖

AI Summary

This exploratory biomarker analysis asked whether repeated hyperbaric oxygen therapy (HBOT) changed circulating anandamide (AEA) or lipopolysaccharide (LPS). It used samples from 17 healthy, physically active men in a randomized parent trial: 9 received 10 HBOT sessions and 8 served as controls. The primary comparison found no significant between-group differences in changes in AEA or LPS; the analysis also found no significant differences for CB2R or FAAH, and no significant within-group changes in the HBOT participants.

As an exploratory result, baseline AEA was positively associated with baseline LPS, but that association does not show that one caused the other. This small, selected biomarker sample cannot establish that HBOT has no smaller effects or that the baseline association is reliable; confirmation in adequately powered studies is needed. This is an abstract-based summary, not a review of the full paper.

💡 Key Findings

1
Among 17 healthy, physically active men, 10 HBOT sessions were not associated with significant between-group changes in anandamide or LPS.
High
95%
2
No significant between-group differences in change were reported for CB2R or FAAH, and the HBOT group had no significant within-group changes.
High
95%
3
Baseline anandamide was positively associated with baseline LPS; this exploratory association does not establish causation and requires confirmation.
High
90%

📄 Original Abstract

BACKGROUND Hyperbaric oxygen therapy (HBOT) can modulate inflammatory and redox-sensitive pathways, but its effects on endocannabinoid system markers remain unclear. This exploratory biomarker subanalysis of a randomized controlled parent trial evaluated whether repeated HBOT was associated with changes in serum anandamide (AEA) and lipopolysaccharide (LPS) as primary outcomes. Cannabinoid receptor type 2 (CB2R), fatty acid amide hydrolase (FAAH), and the baseline AEA-LPS association were assessed secondarily or exploratorily. MATERIAL AND METHODS The resource-limited, post-randomization sample included 17 healthy, physically active men: 9 from a pre-existing morning scheduling subgroup of the frequent-treatment HBOT arm and 8 controls selected before biomarker assays to improve baseline body mass index (BMI) comparability. HBOT consisted of 10 sessions performed 6 times weekly. Each session involved 60 minutes of 100% oxygen at 2.5 atmospheres absolute, delivered as three 20-min oxygen-breathing periods separated by two 5-minute air breaks. Fasting serum was collected before and after the protocol, and biomarkers were measured using enzyme-linked immunosorbent assays. RESULTS No significant between-group differences in change scores were found for AEA (p = 0.597), CB2R (p=1.000), FAAH (p=0.885), or LPS (p=0.885). No significant within-group changes occurred in the HBOT group. Baseline AEA was positively associated with baseline LPS (Spearman's rho=0.505, p=0.039). CONCLUSIONS Receiving 10 HBOT sessions were not associated with significant changes in the measured circulating biomarkers. These exploratory findings do not exclude smaller effects, and the baseline AEA-LPS association requires confirmation in adequately powered studies.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.